Indian pharma giants scuffle to snap up injectables maker Claris
- Claris Lifesciences, based in Ahmedabad, focuses on generic sterile injectables ---an area where demand currently outweighs supply.
- Part of the interest in Claris is fueled by Pfizer's recent $17 billion acquisition of Hospira.
- Injectables are drugs that are used through vials, syringes and bags. Pumps are used to deliver the medications.
Who's bidding? The short list includesLupin, Cipla, Zydus Cadilla and Pfizer. There is also a strong possibility that Dr. Reddy's, Sun Pharma and Novartis are also bidding. This could be the beginning of an M&A trend.